Sandoz to commercialize Pear's reSET digital therapeutics to combat substance abuse; Pear later regains rights
Sandoz International GMBH will lead the commercialization of Pear Therapeutics Inc.'s reSET for substance use disorder (SUD) and reSET-O for opioid use disorder (OUD).
- Digital Health
- Medical Devices
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.